Inventor
HUTCHINGS MARTIN CLIVE
GB21 patents
⚠️ This page may combine multiple inventors who share the name “HUTCHINGS MARTIN CLIVE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELLTECH THERAPEUTICS LTD
5 patentsUS6337335B1Jan 8, 2002
Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
CELLTECH THERAPEUTICS LTD105 citations98
US6235746B1May 22, 2001
Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
CELLTECH THERAPEUTICS LTD290 citations98
US6048866AApr 11, 2000
Substituted 2-anilinopryimidines useful as protein kinase inhibitors
CELLTECH THERAPEUTICS LTD113 citations98
US5958935ASep 28, 1999
Substituted 2-anilinopyrimidines useful as protein kinase inhibitors
CELLTECH THERAPEUTICS LTD361 citations98
US6114333ASep 5, 2000
2-Pyrimidineamine derivatives and processes for their preparation
CELLTECH THERAPEUTICS LTD103 citations96
UCB BIOPHARMA SPRL
5 patentsUS9873703B2Jan 23, 2018
Imidazopyridazine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL8 citations83
US9550737B2Jan 24, 2017
TNF -α modulating benzimidazoles
UCB BIOPHARMA SPRL4 citations71
US10202405B2Feb 12, 2019
Fused pentacyclic imidazole derivatives
UCB BIOPHARMA SPRL4 citations70
US9815797B2Nov 14, 2017
Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL2 citations69
US9309243B2Apr 12, 2016
Imidazopyridine derivatives as modulators of TNF activity
UCB BIOPHARMA SPRL4 citations68
UCB PHARMA SA
3 patentsUCB Biopharma SRL
3 patentsUS10906919B2Feb 2, 2021
Fused pentacyclic imidazole derivatives
UCB Biopharma SRL2 citations70
US11912721B2Feb 27, 2024
Fused pentacyclic imidazole derivatives
UCB Biopharma SRL0 citations60
US10980814B2Apr 20, 2021
Fused pentacyclic imidazole derivatives as modulators of TNF activity
UCB Biopharma SRL0 citations60